PacBio Beats Q1 Loss Estimates as Consumable Revenue Hits Record
PACB sits 82% above its 52-week low of $0.851.
Summary
Pacific Biosciences reported a narrower-than-expected adjusted net loss of $35.9 million for Q1, significantly beating analyst consensus of $44.68 million, with adjusted EPS also surpassing estimates. This positive financial performance comes despite flat year-over-year revenue of $37.2 million, driven by record consumable revenue but offset by weaker-than-expected instrument sales, particularly for its Vega system. The company maintains its full-year 2026 revenue guidance of $165 million to $175 million and plans a broad commercial rollout of its SPRQ-Nx chemistry, anticipating continued growth from increasing clinical adoption of its HiFi technology. This narrowing loss is a notable improvement following the significant net loss reported in 2025, indicating progress in its operational pivot.
At the time of this announcement, PACB was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $498.3M. The 52-week trading range was $0.85 to $2.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.